



- (51) **International Patent Classification:**
C07K 14/705 (2006.01) *A61K 38/16* (2006.01)
- (21) **International Application Number:**
PCT/US2024/015292
- (22) **International Filing Date:**
10 February 2024 (10.02.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/484,286 10 February 2023 (10.02.2023) US
63/588,035 05 October 2023 (05.10.2023) US
- (71) **Applicant:** **BIOHAVEN THERAPEUTICS LTD.**
[US/GB]; Ritter House, P.O. BOX 173, Road Town, Torto-
la, VG1110 (VG).
- (72) **Inventors:** **BECHTOLD, Clifford M.**; Biohaven Pharma-
ceuticals, Inc., 215 Church Street, New Haven, Connecti-

- cut 06510 (US). **CORIC, Vladimir**; Biohaven Pharmaceu-
ticals, Inc., 215 Church Street, New Haven, Connecticut
06510 (US). **QURESHI, Irfan**; Biohaven Pharmaceuticals,
Inc., 215 Church Street, New Haven, Connecticut 06510
(US). **ACKERMAN, Peter J.**; Biohaven Pharmaceuticals,
Inc., 215 Church Street, New Haven, Connecticut 06510
(US). **GRANIT, Volkan**; Biohaven Pharmaceuticals, Inc.,
215 Church Street, New Haven, Connecticut 06510 (US).
- (74) **Agent:** **REMILLARD, Jane E.** et al.; Nelson Mullins Ri-
ley & Scarborough LLP, One Financial Center, Suite 3500,
Boston, MA 02111 (US).
- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

- (54) **Title:** ADMINISTRATION OF FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS TOTREAT OVERWEIGHT, OBESITY, AND RELATED HEALTH CONDITIONS




FIG. 3

- (57) **Abstract:** Provided herein are methods for improving glycemic control in a human patient, methods for treating, preventing, or reducing overweight or obesity and related comorbidities, and methods of treating or preventing type II diabetes, by administering to the patient a polypeptide comprising a fibronectin type III tenth (¹⁰F_n3) domain which binds to myostatin. In some embodiments, the polypeptide is administered (or is for administration) according to a particular clinical dosage regimen (*e.g.*, at particular doses and according to a specific schedule).

[Continued on next page]

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*